Integra LifeSciences (NASDAQ:IART) Shares Up 6.6% – Here’s What Happened

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares were up 6.6% during mid-day trading on Thursday . The company traded as high as $18.54 and last traded at $18.53. Approximately 176,432 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 897,408 shares. The stock had previously closed at $17.38.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wells Fargo & Company raised their target price on Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. Wall Street Zen lowered shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Truist Financial increased their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Finally, Weiss Ratings downgraded shares of Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $18.86.

Integra LifeSciences Price Performance

The stock has a fifty day moving average of $18.02 and a 200-day moving average of $13.84. The firm has a market capitalization of $1.43 billion, a P/E ratio of -203.76, a PEG ratio of 1.54 and a beta of 1.21. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The firm had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors have recently modified their holdings of IART. Hsbc Holdings PLC acquired a new position in Integra LifeSciences in the fourth quarter valued at about $879,000. Tejara Capital Ltd grew its position in shares of Integra LifeSciences by 42.6% during the 4th quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after buying an additional 51,300 shares during the period. Glenmede Trust Co. NA increased its stake in shares of Integra LifeSciences by 27.4% in the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after acquiring an additional 211,774 shares during the last quarter. Paradigm Capital Management Inc. NY increased its stake in shares of Integra LifeSciences by 50.6% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after acquiring an additional 1,347,700 shares during the last quarter. Finally, UBS Group AG raised its position in shares of Integra LifeSciences by 211.7% in the 4th quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock valued at $5,079,000 after acquiring an additional 277,745 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.